Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A hierarchical regulatory network ensures stable albumin transcription under various pathophysiological conditions

ABSTRACT: A hierarchical regulatory network ensures stable albumin transcription under various pathophysiological conditions

PROVIDER: PRJNA751052 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15305658.fastq.gz	Fastqsanger.gz
	SRR15305660.fastq.gz	Fastqsanger.gz
	SRR15305661.fastq.gz	Fastqsanger.gz
	SRR15305662.fastq.gz	Fastqsanger.gz
	SRR15305663.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

A hierarchical regulatory network ensures stable albumin transcription under various pathophysiological conditions

Project description:Physiologically, albumin is produced by hepatocytes. It remains largely unknown how patients are capable of maintaining essential albumin levels even in the condition of liver failure. Here, we delineate a hierarchical regulatory network that controls albumin transcription under different pathophysiological conditions. The ALB core promoter possesses a TATA box and nucleosome-free area, which allows constitutive binding of RNA Pol II and thus initiation of transcription. In normal conditions, HNF4α and C/EBPα facilitate albumin transcription through binding to its promoter. In severely damaged livers, hepatocellular HNF4α and C/EBPα expression is often inhibited. The absence of HNF4 and C/EBPα increases hedgehog ligand biosynthesis. Hedgehog upregulates FOXA2 expression through transcription factor GLI2 binding to the FOXA2 promoter. Subsequently, FOXA2 maintains albumin expression in the hepatocytes lacking HNF4α and C/EBPα. In patients with massive hepatocyte loss, the expression of albumin is activated in liver progenitor cells. Albumin transcription in these cells is regulated by HNF4α or FOXA2. Taken together, HNF4α, C/EBPα and FOXA2 form a hierarchical regulatory network that ensures stable albumin expression even in pathophysiological conditions.

2022-04-06 | GSE181201 | GEO

Albumin, TGF-Beta1 and Blood-Brain Barrier opening induce cortical epileptogenesis.

2009-07-15 | GSE12304 | GEO

Albumin, TGF-Beta1 and Blood-Brain Barrier opening induce cortical epileptogenesis.

Project description:Insults to the cerebral cortex, such as trauma, ischemia or infections, may result in the development of epilepsy, one of the most common neurological disorders. Previous studies have suggested that perturbations in neurovascular integrity and breakdown of the blood-brain barrier (BBB) lead to neuronal hypersynchronization and epileptiform activity, but the underlying mechanisms are unknown. As with BBB opening, treatment with albumin or with TGF-?1 results in the development of hypersynchronized epileptiform activity. Given the latent period before the appearance of epileptiform activity, we hypothesized the underlying mechanism is a transcriptional response which would be similar for BBB breakdown and exposure to albumin or TGF-?1. In search of a common pathway and transcriptional activation pattern we performed a genome wide analysis. Genomic expression analyses demonstrated similar expression patterns for BBB opening, albumin and TGF-?1 exposure. Most importantly, TGF-? pathway blockers suppressed most albumin-induced transcriptional changes. RNA was extracted from cortical regions of rats treated with sodium deoxycholate (DOC, to induce BBB opening), albumin or TGF-?1 for various durations (7/8, 24, 48hr). Control RNA was extracted from a sham-operated animal and one array was run for each treatment and time point A second set of animals (labeled as Set 2) was treated with either albumin (n=3) or albumin in the presence of TGF-? receptor blockers (n=4; TGF-?R1 kinase activity inhibitor SB431542 and TGF-?R2 antibody) and sacrificed 24 hr following treatment. Sham-operated animals served as controls (n=2).

2009-07-15 | E-GEOD-12304 | biostudies-arrayexpress

Albumin-binding RNAi Conjugate for Carrier Free Treatment of Arthritis

Project description:Osteoarthritis (OA) and rheumatoid arthritis (RA) are joint diseases that are associated with pain and lost quality of life. No disease modifying OA drugs are currently available. RA treatments are better established but are not always effective and can cause immune suppression. Here, an MMP13-selective siRNA conjugate (Albumin-binding siMMP13<(EG18L)2) was developed that, when delivered intravenously, docks onto endogenous albumin and promotes preferential accumulation in articular cartilage and synovia of post-traumatic OA (PTOA) and RA (K/BxN) joints. MMP13 expression was diminished upon intravenous delivery of MMP13 siRNA conjugates, consequently decreasing multiple histological and molecular markers of disease severity, while also reducing clinical manifestations such as swelling (RA) and joint pressure sensitivity (RA and OA). Importantly, MMP13 silencing provided more comprehensive OA treatment efficacy than standard of care (steroids) or experimental MMP inhibitors. These data demonstrate the utility of albumin ‘hitchhiking’ for drug delivery to arthritic joints, and establish the therapeutic utility of systemically delivered anti-MMP13 siRNA conjugates in OA and RA.

2023-05-30 | GSE233714 | GEO

Incongruence between transcriptional and vascular pathophysiological cell states

Project description:Incongruence between transcriptional and vascular pathophysiological cell states

| PRJNA967005 | ENA

Expression data from WT SIRT6 and SIRT6 albumin CRE conditional mice

Project description:Microarray analysis of liver tissue from WT SIRT6 and conditional knockout of SIRT6 using albumin-Cre (SIRT6Co/Co ;Alb-Cre) at 2 and 8 months of age

2010-05-28 | GSE21965 | GEO

Transcription profiling by array of human endothelial cell monolayers treated with homocysteinylated albumin

Project description:Endothelial cells monolayers were incubated, for 18h, in the presence of 1.0 ?M N-homocysteinylated albumin. Negative controls were cells incubated with unmodified human serum albumin at a comparable protein concentration and untreated cells.

2011-06-07 | E-MEXP-2771 | biostudies-arrayexpress

Chromatin architecture landscape in hierarchical hematopoietic cells

Project description:Chromatin architecture landscape in hierarchical hematopoietic cells

| PRJNA640930 | ENA

Incongruence between transcriptional and vascular pathophysiological cell states I

Project description:Incongruence between transcriptional and vascular pathophysiological cell states I

| PRJNA955832 | ENA

Incongruence between transcriptional and vascular pathophysiological cell states II

Project description:Incongruence between transcriptional and vascular pathophysiological cell states II

| PRJNA967006 | ENA